注册 | 登录 | 充值

首页-> 学术资讯 -> 临床医学

最新研究表明:美国医生更信任线上学术能力强的制药公司!

临床医学

1970-01-01      

1694 0

by Beth Snyder Bulik | May 9, 2018 8:20am

789.jpg

DRG Digital found pharma companies with up-to-date information and relevant content also scored high on trust with physicians. (Getty/monkeybusinessimages)

When it comes to pharma partners, doctors prefer quality digital content. While that makes sense, new research shows that it also fosters trust with U.S. physicians.

For the first time, DRG Digital’s Manhattan Research queried doctors about which pharma companies they trust in its annual Taking the Pulse survey. They asked a range of questions about those that have quality content, empathy for healthcare providers and a patients-first motivation. However, it was credible scientific content and nonpromotional value adds from pharma that showed the strongest correlation to trust.

And the three drugmakers who ranked as most trusted were Bristol-Myers Squibb, Biogen and Celgene, in that order, among physicians who had digital interactions with them. Not coincidentally, doctors also praised those companies for their strong, relevant online content. 

FREE DAILY NEWSLETTER

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

RELATED: Siri? Alexa? The doctor will see you now: As hands-free tech use grows, pharma has an opportunity

For instance, for top-ranker BMS, 91% of the physicians who had recent interactions with the pharma online agreed it was a trusted partner, while 82% further agreed that it “provides the most up-to-date information and services online.” Biogen was named by 90% of physicians as trusted and 82% noted its valuable content. Celgene, in third place, was trusted by 82% of doctors, with another 77% agreeing that its information was most up-to-date. 

The trust questions were new additions to this year's study, which is now in its 16th year.

“Companies that refresh their digital properties with current digital content seem to be more trusted,” said Matthew Arnold, principal analyst at DRG Digital. “…It may be kind of a dull finding, but if you’re not refreshing your content online, if you’re not adding value to the physician relationship, you’re actually damaging the trust they have in you.”

Heather Figlar, director of U.S. physician research at DRG Digital, added, “Given just how bombarded physicans are and how overworked they are, if you’re going to have a portal up and running, you want to make sure you have refreshed content. Even though it seems like an obvious idea for a good relationship, not all (pharma) companies are doing it.”

RELATED: Pharma rep visits? They're redundant, doctors say in new survey

Along with the importance of keeping up to date, DRG also found that physicians are overwhelmed by emails and advertising and are beginning to opt out of both. Two in five doctors have opted out of professional emails in the past six months, the study found.

But those moves can also be traced back to quality content. Pharma companies that provided consistently relevant content and partnered with trusted third-party publishers avoid getting blocked or spurring unsubscribes.

“Nearly two-thirds said they are most encouraged to open emails if they are from a trusted source, and half pay more attention to prescription drug ads on websites they trust,” he said.



科研资讯(站内): 癌症, 肿瘤, 药物, 医学, 医生, 肿瘤资讯, 肿瘤医生, 肿瘤资讯, 医生工具, 肿瘤文献, 肺癌, 乳腺癌, 肝癌, 患者, 良医汇, 肿瘤诊疗, 肿瘤会诊, 患者招募, 临床试验招募, cancer

百度浏览   来源 : 肿瘤资讯   


版权声明:本网站所有注明来源“医微客”的文字、图片和音视频资料,版权均属于医微客所有,非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源:”医微客”。本网所有转载文章系出于传递更多信息之目的,且明确注明来源和作者,转载仅作观点分享,版权归原作者所有。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。 本站拥有对此声明的最终解释权。

科研搜索(百度):医学科研 癌症, 肿瘤, 药物, 医学, 医生, 肿瘤资讯, 肿瘤医生, 肿瘤资讯, 医生工具, 肿瘤文献, 肺癌, 乳腺癌, 肝癌, 患者, 良医汇, 肿瘤诊疗, 肿瘤会诊, 患者招募, 临床试验招募, cancer





发表评论

注册或登后即可发表评论

登录注册

全部评论(0)

没有更多评论了哦~

科研资讯 更多>>
  • 肿瘤电场治疗Optune Lua获批治疗..
  • 成本更低的实体瘤抗癌新星:CAR-..
  • 文献速递-子宫内膜癌中的卵黄囊..
  • Nature|MSCs首次用于人体跟腱病..
  • 推荐阅读 更多>>
  • 杨衿记教授:OO-1201克唑替尼治..
  • ROS1靶向药物Crizotinib的耐药机..
  • 【综述】免疫检查点阻断剂在淋巴..
  • 韩宝三教授解读第五届中国乳腺外..
    • 相关阅读
    • 热门专题
    • 推荐期刊
    • 学院课程
    • 医药卫生
      期刊级别:国家级期刊
      发行周期:暂无数据
      出版地区:其他
      影响因子:暂无数据
    • 中华肿瘤
      期刊级别:北大核心期刊
      发行周期:月刊
      出版地区:北京
      影响因子:1.90
    • 中华医学
      期刊级别:CSCD核心期刊
      发行周期:周刊
      出版地区:北京
      影响因子:0.94